High HLA-DP Expression and Graft-versus-Host Disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Transplantation of hematopoietic cells from unrelated donors can cure blood disorders but carries a significant risk of acute graft-versus-host disease (GVHD). The risk is higher when the recipient and donor are HLA-DPB1-mismatched, but the mechanisms leading to GVHD are unknown. The HLA-DPB1 regulatory region variant rs9277534 is associated with HLA-DPB1 expression. We tested the hypothesis that the GVHD risk correlates with the rs9277534 allele linked to the mismatched HLA-DPB1 in the recipient. METHODS: We genotyped rs9277534 in 3505 persons to define rs9277534-DPB1 haplotypes. Among 1441 recipients of transplants from HLA-A,B,C,DRB1,DQB1-matched unrelated donors with only one HLA-DPB1 mismatch, linkage of the rs9277534 A and G alleles to the mismatched HLA-DPB1 was determined. HLA-DPB1 expression was assessed by means of a quantitative polymerase-chain-reaction assay. The risk of acute GVHD among recipients whose mismatched HLA-DPB1 allele was linked to rs9277534G (high expression) was compared with the risk among recipients whose mismatched HLA-DPB1 allele was linked to rs9277534A (low expression). RESULTS: The mean HLA-DPB1 expression was lower with rs9277534A than with rs9277534G. Among recipients of transplants from donors with rs9277534A-linked HLA-DPB1, the risk of acute GVHD was higher for recipients with rs9277534G-linked HLA-DPB1 mismatches than for recipients with rs9277534A-linked HLA-DPB1 mismatches (hazard ratio, 1.54; 95% confidence interval [CI], 1.25 to 1.89; P<0.001), as was the risk of death due to causes other than disease recurrence (hazard ratio, 1.25; 95% CI, 1.00 to 1.57; P=0.05). CONCLUSIONS: The risk of GVHD associated with HLA-DPB1 mismatching was influenced by the HLA-DPB1 rs9277534 expression marker. Among recipients of HLA-DPB1-mismatched transplants from donors with the low-expression allele, recipients with the high-expression allele had a high risk of GVHD. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mismatched HLA-DP has been shown to be associated with graft-versus-host disease (47).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Self-citationFord, R., & Eisenberg, S. (1990) · Nursing Clinics of North America · doi:10.1016/s0029-6465(22)02934-6 · Cited by 2,720
Lee, S. J., Klein, J., Haagenson, M., Baxter-Lowe, L. A., Confer, D. L., Eapen, M., Fernandez-Vina, M., Flomenberg, N., Horowitz, M., Hurley, C. K., et al. (2007) · Blood · doi:10.1182/blood-2007-06-097386 · Cited by 1,255
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Sasazuki, T., Juji, T., Morishima, Y., Kinukawa, N., Kashiwabara, H., Inoko, H., Yoshida, T., Kimura, A., Akaza, T., Kamikawaji, N., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391701 · Cited by 526
Kamatani, Y., Wattanapokayakit, S., Ochi, H., Kawaguchi, T., Takahashi, A., Hosono, N., Kubo, M., Tsunoda, T., Kamatani, N., Kumada, H., et al. (2009) · Nature Genetics · doi:10.1038/ng.348 · Cited by 516
Influence of HLA-C Expression Level on HIV Control
Apps, R., Qi, Y., Carlson, J. M., Chen, H., Gao, X., Thomas, R., Yuki, Y., Del Prete, G. Q., Goulder, P., Brumme, Z. L., et al. (2013) · Science · doi:10.1126/science.1232685 · Cited by 371
Self-citationFleischhauer, K., Shaw, B. E., Gooley, T., Malkki, M., Bardy, P., Bignon, J.-D., Dubois, V., Horowitz, M. M., Madrigal, J. A., Morishima, Y., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70004-9 · Cited by 357
Self-citationMajor-Histocompatibility-Complex Class I Alleles and Antigens in Hematopoietic-Cell Transplantation
Petersdorf, E. W., Hansen, J. A., Martin, P. J., Woolfrey, A., Malkki, M., Gooley, T., Storer, B., Mickelson, E., Smith, A., & Anasetti, C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011826 · Cited by 335
Self-citation
Cited by
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Dendrou, C. A., Petersen, J., Rossjohn, J., & Fugger, L. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.143 · Cited by 787
“58) .”
Dehn, J., Spellman, S., Hurley, C. K., Shaw, B. E., Barker, J. N., Burns, L. J., Confer, D. L., Eapen, M., Fernandez-Vina, M., Hartzman, R., et al. (2019) · Blood · doi:10.1182/blood.2019001212 · Cited by 323
Self-citationHow to select the best available related or unrelated donor of hematopoietic stem cells?
Tiercy, J. ‐. (2016) · Haematologica · doi:10.3324/haematol.2015.141119 · Cited by 223
Merkel, P. A., Xie, G., Monach, P. A., Ji, X., Ciavatta, D. J., Byun, J., Pinder, B. D., Zhao, A., Zhang, J., Tadesse, Y., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40034 · Cited by 178
“These variants are in LD with a SNP variant (rs9277534) in the downstream HLA–DPB1 3 0-untranslated region, for which the homozygous genotype is associated with lower levels of HLA–DPB1 and HLA–DP expression in immune cells compared to those in subjects with the alternate homozygous genotype (28,29).”
BackgroundResultShaw, B. E., Logan, B. R., Spellman, S. R., Marsh, S. G. E., Robinson, J., Pidala, J., Hurley, C., Barker, J., Maiers, M., Dehn, J., et al. (2018) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.02.006 · Cited by 177
Self-citationThe Graft-Versus-Leukemia Effect in AML
Sweeney, C., & Vyas, P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01217 · Cited by 173
“However, mismatches have been associated with an increased risk of GvHD and reduction in relapse, consistent with a GvL effect, suggesting that mismatched HLA-DP may represent important antigens in otherwise HLA-matched allo-SCTs (115, 116).”
BackgroundHematopoietic stem cell transplantation in its 60s: A platform for cellular therapies
Chabannon, C., Kuball, J., Bondanza, A., Dazzi, F., Pedrazzoli, P., Toubert, A., Ruggeri, A., Fleischhauer, K., & Bonini, C. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap9630 · Cited by 170
“These so-called permissive mismatches can be identified on the basis of polymorphisms regulating HLA-DP peptide binding (79), surface expression (80), or both and have entered current recommendations for unrelated donor”
BackgroundJuric, M. K., Ghimire, S., Ogonek, J., Weissinger, E. M., Holler, E., van Rood, J. J., Oudshoorn, M., Dickinson, A. M., & Greinix, H. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00470 · Cited by 173
“Recently, Petersdorf and colleagues revealed the mechanism leading to the higher incidence of acute GvHD in recipients of grafts mismatched for HLA-DPB1 (69).”
BackgroundInfluentialNilsson, J. B., Kaabinejadian, S., Yari, H., Kester, M. G. D., van Balen, P., Hildebrand, W. H., & Nielsen, M. (2023) · Science Advances · doi:10.1126/sciadv.adj6367 · Cited by 167
Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells
Ramsuran, V., Naranbhai, V., Horowitz, A., Qi, Y., Martin, M. P., Yuki, Y., Gao, X., Walker-Sperling, V. E. K., Prete, G. Q. D., Schneider, D. K., et al. (2018) · Science · doi:10.1126/science.aam8825 · Cited by 156
Self-citationMayor, N. P., Hayhurst, J. D., Turner, T. R., Szydlo, R., Shaw, B. E., Bultitude, W. P., Sayno, J.-R., Tavarozzi, F., Latham, K., Anthias, C., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.768 · Cited by 134
“Alternative means of determining permissive HLA-DPB1 mismatching according to expression levels have been proposed [31] but are not tested here to avoid further complicating these matching algorithms.”
MethodFuchs, E. J., McCurdy, S. R., Solomon, S. R., Wang, T., Herr, M. M., Modi, D., Grunwald, M. R., Nishihori, T., Kuxhausen, M., Fingerson, S., et al. (2021) · Blood · doi:10.1182/blood.2021013443 · Cited by 127
Self-citationFactors affecting HLA expression: A review
Carey, B. S., Poulton, K., & Poles, A. (2019) · International Journal of Immunogenetics · doi:10.1111/iji.12443 · Cited by 116
“C, and HLA‐DP antigen with both GVHD and mortality (Petersdorf et al., 2014; Petersdorf et al., 2015).”
BackgroundCavalli, G., Hayashi, M., Jin, Y., Yorgov, D., Santorico, S. A., Holcomb, C. L., Rastrou, M. V., Erlich, H., Tengesdal, I. W., Dagna, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1523482113 · Cited by 110
“This paradigm has recently been extended to the MHC: noncoding variation in the HLA-DPB1 region is associated with enhanced clearance of hepatitis B virus infection (23), and with increased risk of graft-versus-host disease in mismatched hematopoietic cell transplant recipients (24).”
BackgroundAdvances in understanding the pathogenesis of graft‐versus‐host disease
Magenau, J. M., Runaas, L., & Reddy, P. R. (2016) · British Journal of Haematology · doi:10.1111/bjh.13959 · Cited by 101
“It is now well established that disparities in major histocompatibility complex (MHC) loci on chromosome 6, as occurs in HLA-mismatched HCT, are directly proportional to the severity of acute GVHD (Flomenberg et al, 2004; Petersdorf et al, 2015).”
BackgroundA subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44
Niehrs, A., García-Beltrán, W. F., Norman, P. J., Watson, G. M., Hölzemer, A., Chapel, A., Richert, L. E., Pommerening‐Röser, A., Körner, C., Ozawa, M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0448-4 · Cited by 98
Self-citationHLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities
Fleischhauer, K., & Shaw, B. E. (2017) · Blood · doi:10.1182/blood-2017-03-742346 · Cited by 94
“The first is based on structural T-cell epitopes (TCEs) shared by subsets of HLA-DPB1 alleles (TCEmodel)(39,62,63); the second considers differences in HLA-DPB1 allele cell-surface expression levels (expression model).(64) The TCE model stems from experimental data showing that T cells alloreactive to HLA-DPB1*09:01 r…”
BackgroundCarapito, R., Jung, N., Kwemou, M., Untrau, M., Michel, S., Pichot, A., Giacometti, G., Macquin, C., Ilias, W., Morlon, A., et al. (2016) · Blood · doi:10.1182/blood-2016-05-719070 · Cited by 88
How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver
McDonald, G. B. (2016) · Blood · doi:10.1182/blood-2015-10-612747 · Cited by 86
“If severe gut and bile duct damage from GVHD is incurable, the focus must be on prevention based on a deeper understanding of pathobiology and explanations for the unexpected appearance of severe GVHD in patients not currently thought to be at risk.(55) A pre-emptive treatment approach, based on falling serum albumin…”
BackgroundChallenges in the application of NGS in the clinical laboratory
Yin, Y., Butler, C., & Zhang, Q. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.03.011 · Cited by 85
Hill, J. A., Magaret, A., Sedlak, R. H., Mikhaylova, A. V., Huang, M.-L. W., Sandmaier, B. M., Hansen, J. A., Jerome, K. R., Zerr, D. M., & Boeckh, M. (2017) · Blood · doi:10.1182/blood-2017-03-775759 · Cited by 82
“Age of recipient, median (IQR) 44 (31-54) 43 (32-56) 41 (31-53) 41 (34-54) Age of donor, median (IQR) 38 (28-48) 34 (26-47) 36 (28-50) 49 (31-59) Sex of recipient Female 1738 (41.”
Transplant genetics and genomics
Yang, J., & Sarwal, M. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.12 · Cited by 81
Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation
Petersdorf, E. W., Bengtsson, M., Santis, D. D., Dubois, V., Fleischhauer, K., Gooley, T. A., Horowitz, M. M., Madrigal, J. A., Malkki, M., McKallor, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00265 · Cited by 79
“High-resolution typing of HLA-DPB1 alleles was performed as described, and ambiguity and G-group allele strings were defined by the parent allele.(25) The expression level of each high-resolution allele was inferred from known exon 2, exon 3, and rs9277534 variation, where rs9277534A-linked alleles were considered low…”
BackgroundMethodResultInfluentialSelf-citationAlloantigen presentation and graft-versus-host disease: fuel for the fire
Koyama, M., & Hill, G. R. (2016) · Blood · doi:10.1182/blood-2016-02-697250 · Cited by 77
“The GI tract, danger signals, and acute GVHD Theprimacy of the gastrointestinal tract in severe, life-threatening acute GVHD is well established.59 The gastrointestinal tract and the colon in particular contain an extensive microbiome60 and as such act as a reservoir for DAMP/PAMP signals, particularly in the context…”
BackgroundInfluentialMallon, D. H., Kling, C., Robb, M. L., Ellinghaus, E., Bradley, J. A., Taylor, C. J., Kabelitz, D., & Kosmoliaptsis, V. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800683 · Cited by 75
HLA-B Leader and Survivorship after HLA-Mismatched Unrelated Donor Transplantation
Petersdorf, E. W., Stevenson, P. A., Bengtsson, M., Santis, D. D., Dubois, V., Gooley, T. A., Horowitz, M. M., Hsu, K. C., Madrigal, J. A., Malkki, M., et al. (2020) · Blood · doi:10.1182/blood.2020005743 · Cited by 73
Self-citationEskandary, F. A., Bond, G., Kozakowski, N., Regele, H. M., Marinova, L., Wahrmann, M., Kikić, Ž., Haslacher, H., Rasoul‐Rockenschaub, S., Kaltenecker, C. C., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001195 · Cited by 72
BSHI guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation
Little, A., Akbarzad‐Yousefi, A., Anand, A., Burlinson, N. D., Dunn, P. P. J., Evseeva, I., Latham, K., Poulton, K., Railton, D., Vivers, S., et al. (2021) · International Journal of Immunogenetics · doi:10.1111/iji.12527 · Cited by 71
The MHC in the era of next-generation sequencing: Implications for bridging structure with function
Petersdorf, E. W., & Ó’hUigín, C. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.10.002 · Cited by 68
“An MHC haplotype library inclusive of regulatory expression variants together with the technology for longrange haplotype phasing may provide the necessary resolution to match haplotypes of transplant patients and donors [78,133], identify patients whose HLA-B-C haplotypes predict risky or protective combinations [23]…”
BackgroundInfluentialSelf-citationCreary, L. E., Gangavarapu, S., Mallempati, K. C., Montero-Martín, G., Caillier, S. J., Santaniello, A., Hollenbach, J. A., Oksenberg, J. R., & Fernández-Viña, M. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.07.275 · Cited by 68
“Maximum 4-field resolution is optimal as it captures allelic variants located within introns and the 5’ and 3’ untranslated regions, which have largely remained unexplored but may play an additional role in protein expression and structural variation [26,27].”
BackgroundAyuk, F. A., Beelen, D. W., Bornhäuser, M., Stelljes, M., Zabelina, T., Finke, J., Kobbe, G., Wolff, D., Wagner, E.-M., Christopeit, M., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.06.026 · Cited by 67
Expression estimation and eQTL mapping for HLA genes with a personalized pipeline
Aguiar, V. R. C., César, J., Delaneau, O., Dermitzakis, E. T., & Meyer, D. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008091 · Cited by 65
“The alleles at this locus were previously divided into two clades, marked by the variant rs9277534 in the 3’-UTR [13, 58, 59].”
Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR
Jiménez, A., Spellman, S. R., Politikos, I., McCurdy, S. R., Devine, S. M., Malki, M. M. A., Bolon, Y., Lee, S. J., Dehn, J. G., Pidala, J. A., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.07.004 · Cited by 66
Self-citationA long road/read to rapid high-resolution HLA typing: The nanopore perspective
Liu, C. (2020) · Human Immunology · doi:10.1016/j.humimm.2020.04.009 · Cited by 66
Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM
Meurer, T., Crivello, P., Metzing, M., Kester, M. G. D., Megger, D. A., Chen, W., van Veelen, P. A., van Balen, P., Westendorf, A. M., Homa, G., et al. (2020) · Blood · doi:10.1182/blood.2020008464 · Cited by 66
Tamouza, R., Krishnamoorthy, R., & Leboyer, M. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.09.033 · Cited by 65
The Past, Present, and Future of HLA Typing in Transplantation
Edgerly, C. H., & Weimer, E. T. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8546-3_1 · Cited by 64
HLA mismatching as a strategy to reduce relapse after alternative donor transplantation
Fleischhauer, K., & Beelen, D. W. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.01.010 · Cited by 63
“were shown to be associated with significantly higher risks of acute GvHD but not of relapse compared to low-expression mismatches [82].”
BackgroundTurner, T. R., Hayhurst, J. D., Hayward, D. R., Bultitude, W. P., Barker, D. J., Robinson, J., Madrigal, J. A., Mayor, N. P., & Marsh, S. G. E. (2017) · HLA · doi:10.1111/tan.13184 · Cited by 62
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances
Chen, S., & van den Brink, M. R. M. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2024.101566 · Cited by 61
Graft versus tumor effects and why people relapse
Falkenburg, J. H. F., & Jedema, I. (2017) · Hematology · doi:10.1182/asheducation-2017.1.693 · Cited by 59
“Several clinical studies have shown that clinical outcome of alloSCT and DLI is influenced by the disparity of HLA-DP between donor and recipient, and it depends in part on the immunogenicity of the mismatched HLA-DP allele for the donor T-cell repertoire.(22,23) Administration of CD4 T cells specific for allo HLA-DP…”
Morishima, S., Shiina, T., Suzuki, S., Ogawa, S., Sato‐Otsubo, A., Kashiwase, K., Azuma, F., Yabe, T., Satake, M., Kato, S., et al. (2017) · Blood · doi:10.1182/blood-2017-08-801449 · Cited by 58
Yamamoto, F., Suzuki, S., Mizutani, A., Shigenari, A., Ito, S., Kametani, Y., Kato, S., Fernandez-Viña, M., Murata, M., Morishima, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00941 · Cited by 52
“The SNP marker rs9277534 is located within the 3′UTR of HLADPB1, and the RNA levels expressed by the AA genotype were reportedly significantly (P 0.001) lower than those expressed by the GG genotype (Figure S3C) (25).”
BackgroundResultInfluentialCrivello, P., Heinold, A., Rebmann, V., Ottinger, H. D., Horn, P. A., Beelen, D. W., & Fleischhauer, K. (2016) · Blood · doi:10.1182/blood-2015-12-686238 · Cited by 55
Schöne, B., Bergmann, S., Lang, K., Wagner, I., Schmidt, A. H., Petersdorf, E. W., & Lange, V. (2017) · Human Immunology · doi:10.1016/j.humimm.2017.11.001 · Cited by 55
“Conserved haplotypes of DPB1 exon 2 and rs9277534 were defined for common DPB1 alleles by direct phasing [9].”
BackgroundSelf-citationYabe, T., Azuma, F., Kashiwase, K., Matsumoto, K., Orihara, T., Yabe, H., Kato, S., Kato, K., Kai, S., Mori, T., et al. (2017) · Leukemia · doi:10.1038/leu.2017.202 · Cited by 54
Noble, J. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1457213 · Cited by 52
“A SNP in the 3 ’ untranslated region of DPB1, rs9277534, was found to correlate with low versus high expression levels of DPB1 expression, and high expression of DP is known to be associated with graft versus host disease (123).”
BackgroundBravo-Egaña, V., Sanders, H., & Chitnis, N. (2021) · Human Immunology · doi:10.1016/j.humimm.2021.01.010 · Cited by 52
BSHI Guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation
Little, A., Green, A., Harvey, J., Hemmatpour, S. K., Latham, K., Marsh, S. G. E., Poulton, K., & Sage, D. A. (2016) · International Journal of Immunogenetics · doi:10.1111/iji.12282 · Cited by 51
HLA Matching in Unrelated Stem Cell Transplantation up to Date
Furst, D. E., Neuchel, C., Tsamadou, C., Schrezenmeier, H., & Mytilineos, J. (2019) · Transfusion Medicine and Hemotherapy · doi:10.1159/000502263 · Cited by 51
Comparison between qPCR and RNA-seq reveals challenges of quantifying HLA expression
Aguiar, V. R. C., Castelli, E. C., Single, R. M., Bashirova, A. A., Ramsuran, V., Kulkarni, S., Augusto, D. G., Martin, M. P., Gutiérrez‐Arcelus, M., Carrington, M. N., et al. (2023) · Immunogenetics · doi:10.1007/s00251-023-01296-7 · Cited by 49
Self-citationMayor, N. P., Wang, T., Lee, S. J., Kuxhausen, M., Vierra‐Green, C., Barker, D. J., Auletta, J. J., Bhatt, V. R., Gadalla, S. M., Gragert, L. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03643 · Cited by 47
“No 898 (17) 325 (16) 573 (18) Yes 503 (10) 188 (9) 315 (10) Male 3,727 (73) 1,521 (75) 2,206 (71)”
Self-citationSequence and Phylogenetic Analysis of the Untranslated Promoter Regions for HLA Class I Genes
Ramsuran, V., Hernández‐Sánchez, P. G., Ó’hUigín, C., Sharma, G., Spence, N., Augusto, D. G., Gao, X., García-Sepúlveda, C. A., Kaur, G., Mehra, N. K., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601679 · Cited by 45
“poietic cell transplantation (18, 19), Parkinson’s disease (20), systemic lupus erythematosus (21), and certain cancers (22–24).”
BackgroundSelf-citationHiguchi, T., Oka, S., Furukawa, H., Tohma, S., Yatsuhashi, H., & Migita, K. (2021) · Human Genomics · doi:10.1186/s40246-020-00301-4 · Cited by 46
“It has also been reported that an SNV in DPB1, rs9277534, is associated with AIH in Japanese populations [57].”
InfluentialYin, Y., Lan, J. H., Nguyen, D., Valenzuela, N. M., Takemura, P., Bolon, Y., Springer, B., Saito, K., Zheng, Y. Y., Hague, T., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165810 · Cited by 44
“In addition, a SNP in the 3’ UTR of HLA-DP has been reported to alter HLA-DP expression [37].”
BackgroundMaking sense of ‘side effects’: Counterpublic health in the era of direct-acting antivirals
Bryant, J., Rance, J., Hull, P., Mao, L., & Treloar, C. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.06.002 · Cited by 42
Petersdorf, E. W. (2017) · F1000Research · doi:10.12688/f1000research.10990.1 · Cited by 42
Self-citationSuzuki, S., Ranade, S., Osaki, K., Ito, S., Shigenari, A., Ohnuki, Y., Oka, A., Masuya, A., Harting, J., Baybayan, P. A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02294 · Cited by 39
“The HLA non-coding SNPs have been associated with disease and regulation of infection such as the SNP in the 3′UTR of HLA-C associated to plasma HIV copy number (19) and the SNP in the 3′UTR of HLA-DPB1 associated to acute GVHD (20).”
BackgroundInfluentialImmunopeptidome Analysis of HLA-DPB1 Allelic Variants Reveals New Functional Hierarchies
van Balen, P., Kester, M. G. D., de Klerk, W., Crivello, P., Arrieta‐Bolaños, E., de Ru, A. H., Jedema, I., Mohammed, Y., Heemskerk, M. H. M., Fleischhauer, K., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000192 · Cited by 39
“alleles correlating with the rs9277534A/G polymorphism, a known expression marker (34).”
BackgroundArrieta‐Bolaños, E., Crivello, P., He, M., Wang, T., Gadalla, S. M., Paczesny, S., Marsh, S. G. E., Lee, S. J., Spellman, S. R., Bolon, Y., et al. (2022) · Blood · doi:10.1182/blood.2022015708 · Cited by 39
Self-citationImmunogenetics of HLA-DP — A New View of Permissible Mismatches
Fleischhauer, K. (2015) · New England Journal of Medicine · doi:10.1056/nejme1505539 · Cited by 38
McDonald, G. B., Tabellini, L., Storer, B. E., Martin, P. J., Lawler, R. L., Rosinski, S. L., Schoch, H. G., & Hansen, J. A. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.04.029 · Cited by 37
Savage, S. A., Viard, M., Ó’hUigín, C., Zhou, W., Yeager, M., Li, S. A., Wang, T., Ramsuran, V., Vince, N., Vogt, A. L., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.01.004 · Cited by 37
Self-citationA high-resolution HLA imputation system for the Taiwanese population: a study of the Taiwan Biobank
Huang, Y., Khor, S., Zheng, X., Chen, H., Chang, Y.-H., Chu, H., Wu, P., Lin, Y., Liao, S., Shen, C., et al. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-0156-3 · Cited by 37
On behalf of the Acute Leukemia Working Party (ALWP) and Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT), Lorentino, F., Labopin, M., Ciceri, F., Vago, L., Fleischhauer, K., Afanasyev, B. V., Kröger, N. M., Cornelissen, J. J., Lovira, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0863-4 · Cited by 37
Herr, W., Eichinger, Y., Beshay, J., Bloetz, A., Vatter, S., Mirbeth, C., Distler, E., Hartwig, U. F., & Thomas, S. (2016) · Leukemia · doi:10.1038/leu.2016.210 · Cited by 37
New insights in HLA ‐E polymorphism by refined analysis of the full‐length gene
Olieslagers, T. I., Voorter, C. E. M., Groeneweg, M., Xu, Y., Wieten, L., & Tilanus, M. G. J. (2017) · HLA · doi:10.1111/tan.12965 · Cited by 37
In silico prediction of nonpermissive HLA-DPB1 mismatches in unrelated HCT by functional distance
Arrieta‐Bolaños, E., Crivello, P., Shaw, B. E., Ahn, K. W., Wang, H., Verneris, M. R., Hsu, K. C., Pidala, J., Lee, S. J., Fleischhauer, K., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018019620 · Cited by 37
“1999-2006 754 (65) 988 (63) 823 (64) 919 (63)”
Self-citationMiyamae, J., Suzuki, S., Katakura, F., Uno, S., Tanaka, M., Okano, M., Matsumoto, T., Kulski, J. K., Moritomo, T., & Shiina, T. (2017) · Immunogenetics · doi:10.1007/s00251-017-1031-5 · Cited by 36
“…HLA-C*14:02 allele and progression after infection of HIV (Apps et al. 2013), and the association of HLA-C*14:02 and HLA-DP5 alleles and acute graft versus host disease (GVHD) (Petersdorf et al. 2014; Petersdorf et al. 2015) has become an important topic in human MHC genetics in recent years.”
BackgroundIn celebration of Ruggero Ceppellini: HLA in transplantation
Petersdorf, E. W. (2017) · HLA · doi:10.1111/tan.12955 · Cited by 35
“Fine mapping of the rs9277534 regulatory region variant and its correlation with HLA-DP expression (as measured by quantitative polymerase chain reaction [qPCR]), identified haplotypes of HLA-DP allotypes and the rs9277534 A or G alleles.(55) In a retrospective study of patients who received HLA-matched unrelated dono…”
BackgroundSelf-citationStockton, J., Nieto, T., Wroe, E., Poles, A., Inston, N. G., Briggs, D., & Beggs, A. D. (2020) · HLA · doi:10.1111/tan.13926 · Cited by 35
“so it includes any DNA variations (in-phase) that, for instance, correspond to expression level or other phenotypes.(20) Although nanopore sequencing is not constrained by the technically demanding nature of other NGS systems this in no way bypasses the requirement for HLA expertise in the authorisation and clinical a…”
BackgroundRegulation of NK-Cell Function by HLA Class II
Niehrs, A., & Altfeld, M. A. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00055 · Cited by 34
Alloreactivity: the Janus-face of hematopoietic stem cell transplantation
for the European Society for Blood and Marrow Transplantation (EBMT), Gratwohl, A. A., Sureda, A. M., Cornelissen, J. J., Apperley, J. F., Dreger, P., Duarte, R. F., Greinix, H., Grath, E. M., Kröger, N., et al. (2017) · Leukemia · doi:10.1038/leu.2017.79 · Cited by 33
Decreasing chronic graft-versus-host disease rates in all populations
Carpenter, P. A., Gooley, T. A., Boiko, J. R., Lee, C. J., Burroughs, L. M., Mehta, R. S., Salit, R. B., Bhatt, N. S., Krakow, E. F., Dahlberg, A. E., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012722 · Cited by 32
Self-citationOran, B., Saliba, R. M., Carmazzi, Y., Lima, M. J. G. D., Rondón, G., Ahmed, S., Alousi, A. M., Andersson, B. S., Anderlini, P. N., Alvarez, M., et al. (2018) · Blood · doi:10.1182/blood-2017-07-798751 · Cited by 32
Geneugelijk, K., Thus, K. A., van Deutekom, H. W. M., Calis, J. J. A., Borst, E., Keşmir, C., Oudshoorn, M., van der Holt, B., Meijer, E., Zeerleder, S. S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00880 · Cited by 32
“More recently also an expression model has been evaluated, which showed that the level of cell-surface expression of HLA-DPB1 mismatches is highly predictive for GVHD after HSCT (46, 47).”
BackgroundTie, R., Zhang, T., Yang, B., Fu, H., Han, B., Yu, J., Tan, Y., & Huang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.15291 · Cited by 32
“Most recent studies attempted to identify permissive mismatches in terms of expression levels of HLA-C and -DPB1 [63, 64].”
BackgroundJohansson, T., Yohannes, D. A., Koskela, S., Partanen, J., & Saavalainen, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.629059 · Cited by 32
“HLA alleles associated with low expression are suggested to be tolerated mismatches and not to increase the risk of GvHD (5, 10, 16) Our data also demonstrated thatmRNA expression differs between HLAhaplotypes.”
BackgroundResultInfluentialGragert, L. A., Spellman, S. R., Shaw, B. E., & Maiers, M. J. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.12.027 · Cited by 31
Self-citationKulkarni, S., Ramsuran, V., Ručević, M., Singh, S., Lied, A. M., Kulkarni, V., Ó’hUigín, C., Gall, S. L., & Carrington, M. N. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700697 · Cited by 31
Self-citationDaniëls, L., Claas, F. H. J., Kramer, C. S. M., Senev, A., den Driessche, M. V., Emonds, M., Laecke, S. V., Hellemans, R., Abramowicz, D., & Naesens, M. (2020) · Transplant Immunology · doi:10.1016/j.trim.2020.101287 · Cited by 31
Fleischhauer, K., Ahn, K. W., Wang, H. L., Zito, L., Crivello, P., Müller, C., Verneris, M. R., Shaw, B. E., Pidala, J., Oudshoorn, M., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.96 · Cited by 30
Self-citationEhrenberg, P. K., Geretz, A., Sindhu, R. K., Vayntrub, T. A., Fernández-Viña, M., Apps, R., Michael, N. L., & Thomas, R. (2017) · HLA · doi:10.1111/tan.13133 · Cited by 30
“Although less often characterized, the HLA-DPB1 locus is of particular interest, as recent studies have shown that its allelic expression levels are variable and associate with Hepatitis B virus clearance, control of Hepatitis C virus replication, and Graft-versus-Host disease.(10,12,13) Of the few NGS-based HLA-DPB1…”
BackgroundCurrent donor selection strategies for allogeneic hematopoietic cell transplantation
Timofeeva, O. A., Philogene, M. C., & Zhang, Q. J. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.08.007 · Cited by 29
Which factors influence the development of GVHD in HLA-matched or mismatched transplants?
Petersdorf, E. W. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.09.003 · Cited by 29
“Risks of GVHD and non-relapse mortality are lower when the patient’s HLA-C and HLA-DPB1 mismatches are expressed at lower than at higher levels [10,11].”
BackgroundSelf-citationVazirabad, I., Chhabra, S., Nytes, J., Mehra, V., Narra, R. K., Szabó, A., Jerkins, J. H., Dhakal, B., Hari, P., & Anderson, M. W. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.006 · Cited by 29
Rimando, J. C., Slade, M., DiPersio, J. F., Westervelt, P., Gao, F., Liu, C., & Romee, R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018025437 · Cited by 29
Ghobadi, A., Milton, D. R., Gowda, L., Rondón, G., Chemaly, R. F., Hamdi, A., Alousi, A. M., Afrough, A., Oran, B., Ciurea, S. O., et al. (2019) · Current Research in Translational Medicine · doi:10.1016/j.retram.2019.01.001 · Cited by 29
Resolving MiSeq-Generated Ambiguities in HLA-DPB1 Typing by Using the Oxford Nanopore Technology
Duke, J. L., Mosbruger, T. L., Ferriola, D., Chitnis, N., Hu, T., Tairis, N. G., Margolis, D. J., & Monos, D. S. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.04.009 · Cited by 29
“polymorphism (SNP) rs9277534 that serves as a marker for DPB1 expression.(26,27) Phase is often broken in intron 2, which is approximately 4 kb in length, and can be either sparsely or densely populated with heterozygous positions, depending on the combination of alleles, and falls in line with the observations regard…”
HLA alleles and haplotypes observed in 263 US families
Osoegawa, K., Mallempati, K. C., Gangavarapu, S., Oki, A., Gendzekhadze, K., Marino, S. R., Brown, N. K., Bettinotti, M. P., Weimer, E. T., Montero-Martín, G., et al. (2019) · Human Immunology · doi:10.1016/j.humimm.2019.05.018 · Cited by 28
Donor Selection for Adults and Pediatrics
Ayuk, F. A., & Balduzzi, A. (2018) · Springer eBooks · doi:10.1007/978-3-030-02278-5_12 · Cited by 28
Montgomery, M. C., Liu, C., Petraroia, R., & Weimer, E. T. (2019) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2019.09.005 · Cited by 28
HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation
Tsamadou, C., Engelhardt, D., Platzbecker, U., Sala, E., Valerius, T., Wagner-Drouet, E., Wulf, G. G., Kröger, N. M., Murawski, N., Einsele, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771449 · Cited by 27
“Moreover, no interaction between HLA-DPB1 and HLA-DRB3/4/5 mismatches was observed in the multivariate analysis, which justified the independent analysis of HLA-DRB3/ 4/5 mismatches on the outcome of HSCT. Previously published studies limited their cohort only to HLA-DPB1-mismatched transplants due to the low numbers…”
BackgroundInfluentialMeurer, T., Arrieta‐Bolaños, E., Metzing, M., Langer, M., van Balen, P., Falkenburg, J. H. F., Beelen, D. W., Horn, P. A., Fleischhauer, K., & Crivello, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02236 · Cited by 27
“We are the first to broaden observations on the genetic control of HLA-DPB1 expression from BLCL and primary unstimulated B cells, in which this issue has been studied so far (5, 8), to other cell types likely to play a role in GvHD, such as DC and IFN-γstimulated B cells and monocytes.”
BackgroundMethodResultInfluentialPatterns of non-ARD variation in more than 300 full-length HLA-DPB1 alleles
Klasberg, S., Lang, K., Günther, M., Schober, G., Massalski, C., Schmidt, A. H., Lange, V., & Schöfl, G. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.05.006 · Cited by 26
Allen, E. S., Yang, B., Garrett, J., Ball, E. D., Maiers, M. J., & Morris, G. P. (2018) · Human Immunology · doi:10.1016/j.humimm.2018.10.008 · Cited by 26
Zou, J., Ciurea, S. O., Kongtim, P., Yi, M., Carmazzi, Y., Rondón, G., Srour, S. A., Partlow, D., Champlin, R. E., & Cao, K. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000797 · Cited by 26
“One model predicted the permissiveness using the TCE grouping(55) and another model was based on specific allele expression levels of the HLA-DPB1 allele.(56) In HSCT with unrelated donors, nonpermissive mismatches are generally associated with increased risk of GVHD that overweighs the GVL benefit and results in an i…”
MethodRegulation of HLA class I expression by non-coding gene variations
Bettens, F., Ongen, H., Rey, G., Bühler, S., Sollet, Z. C., Dermitzakis, E. T., & Villard, J. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010212 · Cited by 25
Overview of Hematopoietic Cell Transplantation for the Treatment of Hematologic Malignancies
Singh, N., & Loren, A. W. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.07.001 · Cited by 25
Metadata
- Authors
- Petersdorf, E. W., Malkki, M., O’hUigin, C., Carrington, M., Gooley, T., Haagenson, M. D., Horowitz, M. M., Spellman, S. R., Wang, T., & Stevenson, P.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Ragon Institute of MGH, MIT and Harvard (US)
- Medical College of Wisconsin (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-13
- Volume
- 373
- Issue
- 7
- Pages
- 599-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4560117
- OpenAlex
- W2258080942
- Cited by
- 278
- References
- 32
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 26 · 2023: 18 · 2022: 20 · 2021: 25 · 2020: 24 · 2019: 33 · 2018: 36 · 2017: 41 · 2016: 30 · 2015: 3
- FWCI
- 28.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Defense (N000141310039)
- Frederick National Laboratory for Cancer Research (HHSN261200800001E.)
- National Institutes of Health (N00014-12-1-0142, #HHSN261200800001E, HHSN261200800001C, CA 18029)
- U.S. Public Health Service (HHSH234200637015C)
- U.S. Navy
- National Heart, Lung, and Blood Institute (U01HL069294)
- Office of Naval Research (N00014-13-1-0039, N00014-14-1-0028, N00014-12-1-0142, N00014-12-1, N00014)
- National Cancer Institute (CA18029, U24CA76518, HHSN261200800001E), CA76518, CA100019, P30CA015704, U24CA076518, R01CA100019, P01CA018029)
- National Institute of Allergy and Infectious Diseases (AI069197, U01AI069197)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Keywords
- HLA-DPB1, HLA-DPB1 mismatch, unrelated donor transplantation, post-transplant mortality, hematopoietic stem cell transplantation
- MeSH terms
- Adolescent, Adult, Female, Genotype, Graft vs Host Disease, Histocompatibility Testing, Humans, Genetic Linkage, Male, Middle Aged, Regulatory Sequences, Nucleic Acid, Proportional Hazards Models, Polymerase Chain Reaction, Hematopoietic Stem Cell Transplantation, Polymorphism, Single Nucleotide, Young Adult, HLA-DP beta-Chains, Unrelated Donors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.